Encorafenib (BRAFTOVI) is a therapeutic drug that targets BRAF gene mutations, which may cause a series of adverse reactions while bringing significant efficacy. Adverse effects of Encorafenib (BRAFTOVI) mainly include common symptoms such as fatigue, nausea, vomiting, and some more serious potential risks.

Adverse effects of Encorafenib (BRAFTOVI)

Understanding the adverse effects of Encorafenib (BRAFTOVI) can help patients and doctors work together to develop a reasonable treatment plan.

Common adverse reactions

When treated with bimetinib, Encorafenib may cause symptoms such as fatigue, nausea, vomiting, abdominal pain, and arthralgia in ≥25% of patients. Common adverse reactions in colorectal treatment with cetuximab include fatigue, nausea, diarrhea, acneiform dermatitis, abdominal pain, decreased appetite, arthralgia and rash. Most of these adverse effects are mild to moderate and may diminish with treatment.

Serious adverse reactions

Encorafenib may also cause some serious adverse reactions, such as bleeding, uveitis, etc. An increase in the incidence of new primary cutaneous and non-cutaneous malignant lesions was observed in patients treated with BRAF inhibitors. Patients may experience bleeding after cannecticafinil, most commonly nosebleeds, hematochezia, and rectal bleeding.

Dose adjustment for adverse effects

For different adverse reactions, the doctor will adjust the dose of Encorafenib according to the specific situation. In the event of adverse effects associated with Encorafenib, dose reduction or discontinuation may be required. When used in combination with strong or moderate CYP3A4 inhibitors, the dose of Encorafenib should also be adjusted to avoid increased blood levels and worsening adverse effects due to drug interactions.

Precautions for the use of Encorafenib (BRAFTOVI)

For the safe and effective use of Encorafenib (BRAFTOVI), patients and physicians need to pay attention to the following medication precautions.

Confirmation of patient information

Before starting Encorafenib, doctors need to confirm whether a patient has a BRAF-V600E or V600K mutation, as Encorafenib is only suitable for patients with these specific gene mutations. Patients also need to be aware of and undergo genetic testing.

Drug interactions

Encorafenib interacts with a variety of drugs, such as strong or moderate CYP3A4 inhibitors and inducers.

When using Encorafenibl, patients need to inform their doctor of all the drugs they are taking to avoid worsening adverse effects or less efficacy due to drug interactions. Doctors also need to adjust the dosage of drugs or choose other appropriate treatment options according to the patient's specific situation.